AI predicts mortality with whole-body MRI for personalized health insights

Researchers developed a deep learning framework for whole-body MRI-based body composition analysis, predicting mortality more accurately than traditional methods. This innovative approach could revolutionize personalized risk assessments and clinical workflows.

Meet this year’s Endpoints 11; J&J winds down cardiovascular and metabolic unit; BMS wins schizophrenia approval; and more

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 29, 2024

Harbour BioMed inks deal up to $395M; ORIC refines plans for two drugs

Plus, news about Idorsia, Enveda, Zymeworks, BerGenBio and Ignota Labs: Harbour BioMed does another deal: The Shanghai-based biotech’s subsidiary, called HBM Alpha Therapeutics, inked a

February 27, 2025

Acadia gets more rights for Daybue, forking over $100M upfront after an ‘impressive’ US launch

Acadia Pharmaceuticals is acquiring further rights to Neuren Pharmaceuticals’ newly approved Rett syndrome treatment for $100 million amid a better-than-expected launch of the drug. The

July 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.